Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Trial details
- Registry ID
- NCT02492711
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerNCT02492711 | MacroGenics | Phase 3 | Completed | 2021-08-11Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |